|
1
|
De Paepe P and De Wolf-Peeters C: Diffuse
large B cell lymphoma: a heterogeneous group of non-Hodgkin
lymphomas comprising several distinct clinicopathological entities.
Leukemia. 21:37–43. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Coiffier B, Thieblemont C, Van Den Neste
E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M,
Sebban C, et al: Long-term outcome of patients in the LNH-98.5
trial, the first randomized study comparing rituximab-CHOP to
standard CHOP chemotherapy in DLBCL patients: a study by the groupe
d'Etudes des lymphomes de l'adulte. Blood. 116:2040–2045. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen CF, He X, Arslan AD, Mo YY, Reinhold
WC, Pommier Y and Beck WT: Novel regulation of nuclear factor-YB by
miR-485-3p affects the expression of DNA topoisomerase IIα and drug
responsiveness. Mol Pharmacol. 79:735–741. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kurokawa K, Tanahashi T, Iima T, Yamamoto
Y, Akaike Y, Nishida K, Masuda K, Kuwano Y, Murakami Y, Fukushima M
and Rokutan K: Role of miR-19b and its target mRNAs in
5-fluorouracil resistance in colon cancer cells. J Gastroenterol.
47:883–895. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Garofalo M, Romano G, Di Leva G, Nuovo G,
Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, et al:
EGFR and MET receptor tyrosine kinase-altered microRNA expression
induces tumorigenesis and gefitinib resistance in lung cancers. Nat
Med. 18:74–82. 2011.PubMed/NCBI
|
|
6
|
Yang Y, Wu J, Guan H, Cai J, Fang L, Li J
and Li M: MiR-136 promotes apoptosis of glioma cells by targeting
AEG-1 and Bcl-2. FEBS Lett. 586:3608–3612. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J,
Jiang B, Shu Y and Liu P: miR-200bc/429 cluster modulates multidrug
resistance of human cancer cell lines by targeting BCL2 and XIAP.
Cancer Chemother Pharmacol. 69:723–731. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Razumilava N, Bronk SF, Smoot RL, Fingas
CD, Werneburg NW, Roberts LR and Mott JL: miR-25 targets
TNF-related apoptosis inducing ligand (TRAIL) death receptor-4 and
promotes apoptosis resistance in cholangiocarcinoma. Hepatology.
55:465–475. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Borel F, Han R, Visser A, Petry H, van
Deventer SJ, Jansen PL and Konstantinova P: Réseau Centre de
Ressources Biologiques Foie (French Liver Biobanks Network),
France: Adenosine triphosphate-binding cassette transporter genes
up-regulation in untreated hepatocellular carcinoma is mediated by
cellular microRNAs. Hepatology. 55:821–832. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pan X, Wang R and Wang ZX: The potential
role of miR-451 in cancer diagnosis, prognosis and therapy. Mol
Cancer Ther. 12:1153–1162. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tagawa H, Ikeda S and Sawada K: Role of
microRNA in the pathogenesis of malignant lymphoma. Cancer Sci.
104:801–809. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fan Y, Song X, Du H, Luo C, Wang X, Yang
X, Wang Y and Wu X: Down-regulation of miR-29c in human bladder
cancer and the inhibition of proliferation in T24 cell via PI3K-AKT
pathway. Med Oncol. 31:652014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cittelly DM, Dimitrova I, Howe EN,
Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR,
Spillman MA and Richer JK: Restoration of miR-200c to ovarian
cancer reduces tumor burden and increases sensitivity to
paclitaxel. Mol Cancer Ther. 11:2556–2565. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheson BD, Pfistner B, Juweid ME, Gascoyne
RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca
E, et al: Revised response criteria for malignant lymphoma. J Clin
Oncol. 25:579–586. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang H, Tan G, Dong L, Cheng L, Li K, Wang
Z and Luo H: Circulating MiR-125b as a marker predicting
chemoresistance in breast cancer. PLoS One. 7:e342102012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bitarte N, Bandres E, Boni V, Zarate R,
Rodriguez J, Gonzalez-Huarriz M, Lopez I, Javier Sola J, Alonso MM,
Fortes P and Garcia-Foncillas J: MicroRNA-451 is involved in the
self-renewal, tumorigenicity and chemoresistance of colorectal
cancer stem cells. Stem Cells. 29:1661–1671. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang JX, Qian D, Wang FW, Liao DZ, Wei
JH, Tong ZT, Fu J, Huang XX, Liao YJ, Deng HX, et al: MicroRNA-29c
enhances the sensitivities of human nasopharyngeal carcinoma to
cisplatin-based chemotherapy and radiotherapy. Cancer Lett.
329:91–98. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hamano R, Miyata H, Yamasaki M, Kurokawa
Y, Hara J, Moon JH, Nakajima K, Takiguchi S, Fujiwara Y, Mori M and
Doki Y: Overexpression of miR-200c induces chemoresistance in
esophageal cancers mediated through activation of the AKT signaling
pathway. Clin Cancer Res. 17:3029–3038. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kopp F, Oak PS, Wagner E and Roidl A:
miR-200c sensitizes breast cancer cells to doxorubicin treatment by
decreasing TrkB and Bmi1 expression. PLoS One. 7:e504692012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu S, Tetzlaff MT, Cui R and Xu X:
miR-200c inhibits melanoma progression and drug resistance through
down-regulation of BMI-1. Am J Pathol. 181:1823–1835. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kong W, He L, Coppola M, Guo J, Esposito
NN, Coppola D and Cheng JQ: MicroRNA-155 regulates cell survival,
growth and chemosensitivity by targeting FOXO3a in breast cancer. J
Biol Chem. 285:17869–17879. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang YP, Chien Y, Chiou GY, Cherng JY,
Wang ML, Lo WL, Chang YL, Huang PI, Chen YW, Shih YH, et al:
Inhibition of cancer stem cell-like properties and reduced
chemoradioresistance of glioblastoma using microRNA145 with
cationic polyurethane-short branch PEI. Biomaterials. 33:1462–1476.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ren Y, Kang CS, Yuan XB, Zhou X, Xu P, Han
L, Wang GX, Jia Z, Zhong Y, Yu S, et al: Co-delivery of as-miR-21
and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell
growth in vitro. J Biomater Sci Polym Ed. 21:303–314. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bai H, Wei J, Deng C, Yang X, Wang C and
Xu R: MicroRNA-21 regulates the sensitivity of diffuse large B-cell
lymphoma cells to the CHOP chemotherapy regimen. Int J Hematol.
97:223–231. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang X, Huang L, Zhao Y and Tan W:
Downregulation of miR-130a contributes to cisplatin resistance in
ovarian cancer cells by targeting X-linked inhibitor of apoptosis
(XIAP) directly. Acta Biochim Biophys Sin (Shanghai). 45:995–1001.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou YM, Liu J and Sun W: MiR-130a
overcomes gefitinib resistance by targeting met in non-small cell
lung cancer cell lines. Asian Pac J Cancer Prev. 15:1391–1396.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang L, Li N, Wang H, Jia X, Wang X and
Luo J: Altered microRNA expression in cisplatin-resistant ovarian
cancer cells and upregulation of miR-130a associated with
MDR1/P-glycoprotein-mediated drug resistance. Oncol Rep.
28:592–600. 2012.PubMed/NCBI
|
|
29
|
Xu N, Shen C, Luo Y, Xia L, Xue F, Xia Q
and Zhang J: Upregulated miR-130a increases drug resistance by
regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell.
Biochem Biophys Res Commun. 425:468–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kosaka N, Iguchi H and Ochiya T:
Circulating microRNA in body fluid: a new potential biomarker for
cancer diagnosis and prognosis. Cancer Sci. 101:2087–2092. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
LaConti JJ, Shivapurkar N, Preet A,
Deslattes Mays A, Peran I, Kim SE, Marshall JL, Riegel AT and
Wellstein A: Tissue and serum microRNAs in the Kras(G12D)
transgenic animal model and in patients with pancreatic cancer.
PLoS One. 6:e206872011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mahn R, Heukamp LC, Rogenhofer S, von
Ruecker A, Müller SC and Ellinger J: Circulating microRNAs (miRNA)
in serum of patients with prostate cancer. Urology. 77:1265.e9–e16.
2011. View Article : Google Scholar
|
|
33
|
Li HY, Zhang Y, Cai JH and Bian HL:
MicroRNA-451 inhibits growth of human colorectal carcinoma cells
via down-regulation of Pi3k/Akt pathway. Asian Pac J Cancer Prev.
14:3631–3634. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen H, Untiveros GM, McKee LA, Perez J,
Li J, Antin PB and Konhilas JP: Micro-RNA-195 and −451 regulate the
LKB1/AMPK signaling axis by targeting MO25. PLoS One. 7:e415742012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
He L, Wang HY, Zhang L, Huang L, Li JD,
Xiong Y, Zhang MY, Jia WH, Yun JP, Luo RZ and Zheng M: Prognostic
significance of low DICER expression regulated by miR-130a in
cervical cancer. Cell Death Dis. 5:e12052014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li B, Huang P, Qiu J, Liao Y, Hong J and
Yuan Y: MicroRNA-130a is down-regulated in hepatocellular carcinoma
and associates with poor prognosis. Med Oncol. 31:2302014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim SW, Ramasamy K, Bouamar H, Lin AP,
Jiang D and Aguiar RC: MicroRNAs miR-125a and miR-125b
constitutively activate the NF-κB pathway by targeting the tumor
necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl
Acad Sci USA. 109:7865–7870. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Davoudi Z, Akbarzadeh A, Rahmatiyamchi M,
Movassaghpour AA, Alipour M, Nejati-Koshki K, Sadeghi Z,
Dariushnejad H and Zarghami N: Molecular target therapy of AKT and
NF-kB signaling pathways and multidrug resistance by specific cell
penetrating inhibitor peptides in HL-60 cells. Asian Pac J Cancer
Prev. 15:4353–4358. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Compagno M, Lim WK, Grunn A, Nandula SV,
Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano
A, et al: Mutations of multiple genes cause deregulation of
NF-kappaB in diffuse large B-cell lymphoma. Nature. 459:717–721.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen J, Wang W, Zhang Y, Chen Y and Hu T:
Predicting distant metastasis and chemoresistance using plasma
miRNAs. Med Oncol. 31:7992014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sehn LH, Berry B, Chhanabhai M, Fitzgerald
C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J,
et al: The revised international prognostic index (R-IPI) is a
better predictor of outcome than the standard IPI for patients with
diffuse large B-cell lymphoma treated with R-CHOP. Blood.
109:1857–1861. 2007. View Article : Google Scholar : PubMed/NCBI
|
